HSA | FSA CARDS ARE NOW ACCEPTED

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on hormones and fertility. Browse all Hormones & Fertility education

Women's hormone health isn't just about how much estrogen you make — it's about how you clear it. Two women can produce identical amounts of estrogen and have completely different experiences, from cycle patterns to PMS intensity to perimenopause timing to HRT response. The variance lives in clearance: the Phase 1 enzymes that begin estrogen breakdown, the Phase 2 enzymes that finish it, the methylation system that powers both, and the receptors that translate the signal into cellular action. The Precision Peptide Genetic Test analyzes the genes that govern each of these systems — part of a broader panel spanning 14 pathways, 49 peptides, and 150+ genetic insights. This pillar guide walks through what each gene measures, why clearance matters as much as production, and how to translate your results into an informed hormone conversation with a qualified healthcare provider.

Production vs. Clearance — The Distinction Most Hormone Content Misses

Most hormone conversations focus on production: how much estrogen is being made. But the genetic panel for women's hormone health is largely about clearance — what happens after estrogen has done its job. If your body produces a normal amount of estrogen but clears it slowly, catechol estrogens accumulate, Phase 2 detox load rises, and symptoms show up even though your lab values read "normal." Flip it: fast clearance at the same production level can look like low-estrogen symptoms. The 6 Reproductive Health insights in the Precision Peptide Genetic Test map onto this entire clearance architecture.

Phase 1 Metabolism — CYP1A1 and CYP1B1

Phase 1 converts estradiol into three catechol estrogen metabolites: 2-hydroxy (2-OH), 4-hydroxy (4-OH), and 16-hydroxy (16-OH). The ratio matters. 2-OH is generally considered the cleanest metabolite. 4-OH carries more potential for oxidative stress because it can form reactive intermediates. 16-OH tends toward the most proliferative profile. CYP1A1 favors 2-OH production. CYP1B1 favors 4-OH. Common variants at either gene shift the ratio — which shifts the downstream load on Phase 2 clearance and the methylation system.

COMT — The Methylation Branch of Phase 2 Clearance

COMT (catechol-O-methyltransferase) methylates catechol estrogens into forms that can be excreted. The Val158Met variant changes COMT activity by roughly 3–4 fold. Val/Val produces fast clearance. Val/Met is intermediate. Met/Met is slow clearance — catechol estrogens hang around longer, contributing to accumulation pressure at equivalent production levels. COMT doesn't cause any specific symptom profile on its own; it stacks with CYP1A1, CYP1B1, and methylation status to shape the full clearance picture.

MTHFR — Powering the Methylation Engine

COMT can't function without methyl donors, and methyl donors come from the methylation cycle that MTHFR runs. Common MTHFR variants — C677T and A1298C — reduce enzyme activity by 30–70% depending on genotype. Slow MTHFR means fewer methyl donors, which means COMT has less fuel, which means catechol estrogens clear more slowly. This is the MTHFR-COMT intersection, one of the most important concepts in women's hormone genetics — and a key reason methylation support shows up in so many women's hormone protocols.

SULT1A1 and GSTM1/GSTT1 — The Other Phase 2 Pathways

Methylation isn't the only Phase 2 clearance route. SULT1A1 runs the sulfation pathway, attaching sulfate groups to estrogen metabolites. GSTM1 and GSTT1 run the glutathione conjugation pathway, neutralizing reactive estrogen metabolites. Common GSTM1 and GSTT1 null variants mean completely absent enzyme activity — these women rely more heavily on methylation and sulfation to finish clearance. Variants across all three genes shape how much redundancy your Phase 2 system has when methylation is slow or overloaded.

ESR1 and ESR2 — Receptor Sensitivity

Once estrogen is made and metabolized, receptor binding is where the biological effect happens. ESR1 encodes estrogen receptor alpha (dominant in uterus, breast, bone). ESR2 encodes estrogen receptor beta (dominant in brain, cardiovascular tissue, immune cells). Common variants in both genes influence tissue sensitivity. A woman with less sensitive receptors may need higher estrogen levels to feel "normal." A woman with more sensitive receptors may be symptomatic at lower levels. This gene pair is foundational for understanding why the same HRT protocol can produce radically different experiences across women with similar lab values.

Beyond Women's Hormone: How Your Panel Connects

Female hormone biology doesn't live in one pathway. Your 6 Reproductive Health insights intersect with the 8 Mood insights (estrogen heavily influences serotonin and dopamine), the 6 Sexual Health insights (via crossover to DRD2, eNOS, and oxytocin pathways), the 12 Energy Metabolism insights (estrogen shapes mitochondrial function), and the 34 Weight Management insights (estrogen and metabolic aging are deeply entangled in perimenopause). For a full overview of what the Precision Peptide Genetic Test covers, see our guide to genetic peptide testing. The Peptide Pathways Report synthesizes these cross-pathway findings into a single actionable roadmap.

Genetics as a Guide, Not a Guarantee

Your results don't diagnose any condition, and they don't prescribe a protocol. What they do is reveal the biological terrain your hormone strategy has to operate on. A slow-COMT, slow-MTHFR profile means methylation support carries more weight in any hormone plan. A fast-CYP1B1 variant means Phase 2 load runs higher. ESR1 variants shape how sensitively your tissues respond — implications for dose calibration conversations with a qualified provider. The real win is replacing generic hormone advice with decisions calibrated to your actual biology — the premise of testing before you invest in a hormone protocol.

The Precision Peptide Genetic Test analyzes how your genes influence women's hormone pathways. It does not recommend, prescribe, or determine which peptides you should use. Consult a qualified healthcare provider before beginning any peptide protocol.

Ready to see your women's hormone genetic profile? Take the Precision Peptide Genetic Test

Frequently Asked Questions

How many genes does women's hormone testing cover in the PlexusDx panel?

The Precision Peptide Genetic Test analyzes women's hormone genetics as part of 6 Reproductive Health insights across 14 pathways, 49 peptides, and 150+ genetic insights. Core genes include COMT, CYP1A1, CYP1B1, MTHFR, ESR1, SULT1A1, and GSTM1/GSTT1 — covering estrogen production, clearance, and receptor sensitivity. Processed via Illumina Global Screening Array at CLIA-certified labs.

Why do two women with the same estrogen levels feel different?

Genetics. COMT, CYP1A1, and MTHFR determine how efficiently you clear estrogen — slow variants produce more accumulation at the same production level. ESR1 and ESR2 determine how sensitively your tissues respond. Identical estrogen levels feel different depending on clearance speed and receptor sensitivity. Part of 6 Reproductive Health insights in the Precision Peptide Genetic Test.

Can genetic testing tell me if HRT will work for me?

No — the Precision Peptide Genetic Test informs the conversation, not the prescription. Your 6 Reproductive Health insights reveal how you metabolize estrogen (CYP1A1, CYP1B1), clear catechol estrogens (COMT, MTHFR), and respond to estrogen signaling (ESR1, ESR2). These shape how a qualified healthcare provider approaches hormone optimization — the protocol is theirs to make.

This article is part of the PlexusDx Education Hub. Browse all Hormones & Fertility education